Eisai Announces Initiation of Phase III BAN2401 Study in Alzheimer's Disease
March 22, 2019 at 06:50 AM EDT
Eisai announced that a global Phase III clinical study of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated.
